Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today
Key takeaways
- Moderna’s Phase‑3 win could pivot the company toward oncology, while Webull, Bitmine, Strategy, and Merck all benefited from strong earnings or market sentiment, driving significant intraday gains.
- Moderna shares up 176.97% to $174.38
- Webull Q2 revenue $198.83 million (51% YoY)
- Webull adjusted EPS $0.05 vs $0.03 expected
What happened
Moderna’s shares surged 176.97% to $174.38 after announcing a Phase‑3 melanoma trial win for its personalized mRNA cancer vaccine in partnership with Merck, marking the first Phase‑3 success for an mRNA‑based oncology therapy. Webull’s stock rose 8.95% to $8.64 on stronger‑than‑expected Q2 revenue of $198.83 million (up 51% YoY) and adjusted EPS of $0.05 versus $0.03 expected, while customer assets climbed 79% to $28.5 billion. Bitmine Immersion Technologies gained 10.72% to $20.24 as…
Why it matters
The Moderna breakthrough signals a potential shift from a pandemic‑focused company to a viable oncology platform, potentially expanding its revenue base and investor appeal. Webull’s solid Q2 results and asset growth reinforce its position as a leading retail brokerage, suggesting continued momentum in the fintech…
Short-term and longer-term
Short-term. Moderna’s stock is now a high‑volatility play; traders should watch for any post‑market commentary on the trial data and potential regulatory filings.
Longer-term. Moderna’s Phase‑3 melanoma success could broaden its revenue streams into oncology, potentially justifying a higher valuation multiple over the next 12–18 months.